Summary
Background Biological therapies are highly effective in psoriasis, but have profound effects on innate and adaptive immune pathways that may negatively impact on cancer immunosurveillance mechanisms. Objectives To investigate the risk of cancer in patients with psoriasis treated with biological therapy. Methods We searched MEDLINE, Embase, and the Cochrane Library (up to August 2016) for randomized controlled trials, prospective cohort studies and systematic reviews that reported cancer incidence in people exposed to biological therapy for psoriasis compared with a control population. Results Eight prospective cohort studies met our inclusion criteria. All the evidence reviewed related to tumour necrosis factor inhibitors (TNFi) with the exception of one study on ustekinumab. An increased risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma, was reported with TNFi compared with both a general United States population and a rheumatoid arthritis population treated with TNFi. No evidence for increased risk of cancers (reported as all cancers, lymphoma, melanoma, prostate, colorectal and breast cancer) other than NMSC was identified. Conclusions There were important limitations to the studies identified including choice of comparator arms, inadequate adjustment for confounding factors and failure to account for latency periods of cancer. There remains a need for ongoing pharmacovigilance in relation to cancer risk and biological therapy; the NMSC signal requires further investigation to determine the risk specifically attributable to biological therapy using prospectively collected data with adjustment for known NMSC risk factors.
What's already known about this topic?
• The risk of cancer in biologics-exposed patients with psoriasis is poorly understood. While the risk is reasonably well characterized in other chronic autoimmune conditions, these findings cannot be extrapolated to patients with psoriasis.
What does this study add?
• This systematic review summarizes the current literature for cancer risk in biologics-exposed patients with psoriasis.
• Signals are emerging that exposure to tumour necrosis factor inhibitors is associated with increased risk of nonmelanoma skin cancers in people with psoriasis, but comparator groups identified were historic and studies lack adjustment for highly relevant confounding factors such as prior phototherapy.
• Long-term pharmacovigilance is still required to establish whether there is a risk of cancer directly attributable to biological therapy.
Biological agents licensed for use in psoriasis include tumour necrosis factor inhibitors (TNFi) (etanercept, infliximab and adalimumab), and antagonists of the interleukin (IL)-17 pathway (ustekinumab, secukinumab and ixekizumab). 1 Realworld data accumulated from pharmacovigilance registries show these agents to be generally well tolerated and effective in clinical practice. [2] [3] [4] [5] However, biological therapies have profound effects on innate and adaptive immune pathways that may be relevant to cancer immunosurveillance mechanisms, with TNFi in particular targeting IL-1 and IL-6 in cancer pathways. 6 Prospective cohort studies in other immune-mediated inflammatory diseases, such as rheumatoid arthritis 7, 8 and psoriatic arthritis, 9 provide some reassurance regarding risk of cancer following treatment with biologics, although these findings may not be generalizable to psoriasis. Increased rates of cancer including nonmelanoma skin cancers (NMSCs), lymphoma and colorectal cancers have been reported in psoriasis per se, 10 so establishing risk specifically attributable to biological therapies is not straightforward. 'Generic' population risk factors, such as demographics (age, ethnicity, family or personal history of cancer), obesity, smoking, or alcohol excess need to be taken into account. Disease-specific factors are also relevant: for example, maladaptive coping mechanisms may be associated with more smoking and alcohol excess. 11 Most patients receiving biological therapies for psoriasis will have had prior exposure to 'nonbiological' systemic immunosuppression and, of relevance to skin cancer, phototherapy, all of which may drive risk. 12, 13 To date, psoriasis treatment guidelines have provided recommendations based on the theoretical concerns about risk of cancer. 14, 15 These aim to protect patients but may be limiting access for those who are perceived to be at risk. 16 Given that biological agents have been in use for over 15 years 16, 17 and considering the latency period for developing a cancer, it is reasonable to review the evidence for long-term risk of cancer now. We have therefore performed a systematic review to investigate the risk of cancer in patients with psoriasis who have specifically been treated with biologics, focusing on studies with a defined comparator arm and follow-up of at least 6 months. This review will be used to inform the updated British Association of Dermatologists guidelines for use of biological therapies in psoriasis. 18 
Materials and methods
The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO; 2015:CRD42015017538).
Predefined search strategy and selection criteria
An a priori protocol was established as follows (the complete protocol is given in File S1, section 1; see Supporting Information). The objective was to determine the risk of cancer in people with psoriasis (all phenotypes) exposed to biologics. The outcome of interest was incidence of any cancer in studies with follow-up of ≥ 6 months using the initiation of biological treatment or a reference starting time-point. Data for different cancers were summarized separately (NMSCs, melanoma, lymphoma and solid cancers). The primary population included all patients with psoriasis treated with biologics. Only studies with a comparator arm were included. Analysis by strata (cancers and psoriatic arthritis) and confounding factors considered for subgroup analysis are listed in File S1. Systematic reviews, randomized controlled trials (RCTs), open-label extension (OLE) studies, and prospective cohort studies on any biologic were included. Studies with indirect populations were excluded; populations where the proportion being treated primarily for psoriatic arthritis was > 50% were considered indirect.
Search and study selection
The systematic literature search was performed in MEDLINE, Embase, and the Cochrane Library from inception until August 2016, with the results deduplicated, titles reviewed and irrelevant studies excluded by an information scientist (L.E.). The search strategy and search terms are available in File S1, sections 2Á1-2Á3. Studies reported in languages other than English were excluded.
The abstracts were screened by two assessors (L.E. and E.P.), and disagreements resolved by a third (C.S.). The fulltext articles were obtained and checked against the protocol and those that did not meet the criteria were excluded (L.E., C.S. and E.P.). Reference lists of systematic reviews and metaanalyses were screened for additional papers (L.E. and E.P.).
Data extraction and quality assessment
Data extraction and appraisal was performed using a standardized template (E.P.) and repeated by a second researcher (L.E.), and differences were resolved by a third independent assessor (C.S.). Data collected included: study details (study type, data source, setting, duration of study, funding sources), population details (disease severity, subgroup analysis, number of groups/participants, selection criteria, age, sex, ethnicity, exposure to previous phototherapy, previous immunosuppression, comorbidities including smoking and alcohol, psoriatic arthritis, body weight, previous cancers, family history of cancers), interventions, and results (type and number of cancers; when these developed).
The methodological quality was assessed for individual studies using the Cochrane Collaboration's tool for assessing risk of bias. 19 Adjustment for or consideration of potential confounders was also evaluated.
Data analysis
Where possible, meta-analyses were planned. If not appropriate, descriptive statistics were used to summarize the data.
Results
The systematic literature search yielded 4566 results after duplicates were removed ( Fig. 1 ). Of these, 245 abstracts were screened, and 63 full-text articles were assessed for eligibility. Seventeen additional papers were identified through handsearching reference lists of systematic reviews. Data were extracted from eight prospective cohort studies that met the inclusion criteria. The studies and reasons for exclusion are listed in File S1, section S3. In summary, reasons for study exclusion were lack of a comparator arm (n = 26), duplicate publication (n = 20), follow-up < 6 months (n = 7), no extractable data (n = 10), indirect populations (n = 4), retrospective design (n = 1), outside of scope (n = 3, one study was on tildrakizumab; two did not look at biologics), or study was withdrawn (n = 1) (Fig.1) .
Risk of bias
Using the Cochrane Collaboration's tool for assessing risk of bias, the overall risk of bias for all of the studies was rated as very high (Table 1) . 19 Risk of selection bias was low in seven of eight studies (88%); it was graded high in van Lumig et al. 20 as data collected from hospital registries risks missing some events due to misclassification and there is a potential risk of surveillance bias. Given that the outcome is objective, the risk of performance bias was low in all studies. The risk of attrition bias was high for all studies. Risk of detection or measurement bias was high in seven of eight studies. Research was funded by pharmaceutical companies (n = 7) or it was not reported (n = 1). The outcome was defined as patients with cancer (n = 3), [21] [22] [23] as cancers (n = 2) 24, 25 or both (n = 3). 20, 26, 27 The quality of the evidence across all studies was very low, due to the high risk of bias. The studies could not be pooled for meta-analysis due to differences in the biological therapies investigated, variable exposure lengths, variable outcome definitions, incomplete data and no adequate control for key confounding factors other than age and sex. The data were therefore summarized using descriptive statistics.
Confounding factors
Confounding factors were either poorly reported or not reported (Table 2) . No studies reported skin type. In the six studies that reported ethnicity, > 80% of patients were white (range 81Á1-96Á4%). [21] [22] [23] [25] [26] [27] Sex-and age-matched comparison cohorts were used in seven of eight studies; adjustment for age or sex, or for other confounders, was not reported in Pariser et al. 27 In van Lumig et al. 20 multiple confounders were adjusted for but it is unclear whether the remaining six studies adjusted for the confounding factors.
Study characteristics
The main study characteristics are summarized in Table 3 , including: RCTs or OLE studies (n = 6); a post-marketing surveillance registry (n = 1); and prospective registries from medical centres (n = 1). The studies included between 280 and 4410 patients located in North America (n = 2), Europe
Unable to obtain full text of articles n = 0
Full-text articles n = 63
Additional papers from reference lists of retrieved papers n = 17
Full-text articles assessed for eligibility n = 80
Articles included in qualitative synthesis n = 8
Full-text articles excluded with reasons n = 72
Abstracts screened n = 245
Excluded by abstract n = 182
Excluded by title n = 1927
Titles screened after duplicates removed n = 2172
Records identified through database search n = 4566 (n = 1), or internationally (n = 5). Patients in the intervention groups received etanercept (n = 3 studies), infliximab (n = 1), adalimumab (n = 2), multiple TNFi class (n = 1), or ustekinumab (n = 1). Studies included patients with plaque-type psoriasis only (n = 6), or it was not reported (n = 2), and disease severity was moderate to severe on the Physician Global Assessment scale in most studies. The majority of patients were male (52Á4-68Á5%), and mean age ranged from 44-47 years. A variety of comparator arms were used. Six studies investigating any cancers excluding NMSCs used the U.S. National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database; four studies used data recorded between 1992 and 2003, [24] [25] [26] [27] and two studies did not report the time period used. 22, 23 In order to investigate the risk of patients who received methotrexate and/or ciclosporin for other unspecified inflammatory conditions identified through insurance claims databases as the comparator arm for all outcomes; in van Lumig et al. 20 the intervention (patients with psoriasis) and comparator arms (rheumatoid arthritis) exposed to TNFi were identified from two hospital registries. All of the studies included a biologics cohort of patients with psoriasis with mixed prior exposure to biologics, conventional systemics and/or phototherapy; none of the studies included a biologics-naive comparator arm of patients with psoriasis.
Risk of cancers

Any cancers
Compared with the general U.S. population, standardized incidence ratios (SIRs) show no increased risk in patients with psoriasis of 'any cancers excluding NMSC' with TNFi therapies TNFi, tumour necrosis factor inhibitor. General U.S. population 3010; 0Á5 years (median), 5Á5 years (max.) BCC, basal cell carcinoma; CI, confidence interval; HR, hazard ratio; max., maximum length; MTX, methotrexate; NMSC, nonmelanoma skin cancer; RA, rheumatoid arthritis; RR, risk ratio; SCC, squamous cell carcinoma; SIR, standardized incidence ratio; TNFi, tumour necrosis factor inhibitor. or ustekinumab (Table 4 ). There was no increased risk with etanercept compared with patients on nonbiological systemic therapies for other inflammatory conditions (conditions not reported).
Skin cancers
Four studies investigated the risk of NMSC in patients with psoriasis on TNFi therapies (Table 4 ). In the two studies reporting data on adalimumab, there was an increased risk of NMSC compared with the general U.S. population [SIR 1Á76, 95% confidence interval (CI) 1Á26-2Á39; and SIR 1Á51, 95% CI 1Á04-2Á11, respectively]. 24, 25 We believe there is considerable overlap in the data presented in these studies based on the number of trials and patients reported, despite marginal differences in the reported results. Consistent with the previous findings, an increased risk of NMSC was reported in patients receiving TNFi for psoriasis compared with those with rheumatoid arthritis (adjusted hazard ratio 6Á0, 95% CI 1Á6-22Á4 and adjusted risk ratio 5Á5, 95% CI 2Á2-13Á4). 20 This risk may be driven by an increase in squamous cell carcinoma (SCC) with increases reported with both etanercept (SIR 1Á78, 95% CI 1Á11-2Á69 and SIR 4Á28, 95% CI 2Á68-6Á47) and adalimumab (SIR 3Á84, 95% CI 1Á54-7Á92) compared with a general U.S. population. 25, 27 Only one study specifically evaluated the risk of melanoma in those receiving ustekinumab, and found no increased incidence compared with a general U.S. population (Table 4) .
Solid cancers and lymphoma
SIRs showed no increased incidence of prostate, colorectal or breast cancer for ustekinumab compared with the general U.S. population. SIRs for lymphoma demonstrated no increased risk; however, fewer than five events were reported for patients with psoriasis exposed to etanercept, 21 adalimumab 24 and ustekinumab. 23 The median follow-up for studies evaluating risk of lymphoma was only 0Á5 years for adalimumab, and 5-7 years for etanercept and ustekinumab (Table 4 ). The incidence of lymphoma was 0Á11 and 0Á13 per 1000 person years for etanercept and ustekinumab, respectively.
Discussion
This systematic review provides an up-to-date synthesis of the published evidence regarding the risk of cancer with biological therapies in patients with psoriasis and is the first to specifically address the long-term incidence of cancer in this population. The most significant finding in this review is the increased risk of NMSCs, associated with exposure to TNFi. This risk appears to be driven by an increase in SCC, which is consistent with findings observed with nonbiological 'immunosuppression'. 12, 13 However, there are important limitations to the design and reporting of the included studies that make it difficult to be certain that this signal is specifically attributable to biological therapy.
Firstly, the comparator arms are problematic. As patients with psoriasis who were exposed to nonbiological therapies were not included in any comparator arms, it is impossible to determine whether the incidence rates of cancer were further elevated following exposure to biologics. 10 26, 27 Not only do these general population cohorts fail to account for confounders present in the psoriasis population (including phototherapy and conventional systemic therapies), but these cohorts are also not contemporaneous with the cohorts of biologic-exposed patients with psoriasis. NMSC incidence has significantly increased over time, as demonstrated by incidence rates in Germany more than doubling between 1998 (43 per 100 000 population) and 2010 (105 per 100 000 population). 28 Comparing NMSC risks at distinct time points may lead to inflated risk estimates. Secondly, two of the studies compared the overall incidence of cancer in the intervention group (i.e. multiple cancers per patient) to the incidence of first-time diagnosis of cancer in the comparison cohort. 24, 25 Therefore the increased SIRs for
NMSCs may be related to overestimating incidence by counting the number of cancers. Thirdly, the studies did not adequately control for key confounders other than age and sex (including previous phototherapy, prior exposure to immunosuppression and previous NMSCs). 13, 29 Outcomes were not separately reported for patients who had a history of cancer, and only one study corrected for history of previous NMSC. 20 Clinical trials have historically excluded patients with a history of cancer; six studies present data from RCTs and open-label studies, and at least one excluded patients with history of cancer as above, 20 while the other studies do not report full exclusion criteria. In van Lumig et al., 20 although the authors correct for confounders, they do not correct for ultraviolet (UV) exposure (Table 2 ). This could partly explain the high adjusted hazard ratio and risk ratio for NMSC. 30 While the data on the risk of cancers other than NMSCs in the present review are reassuring, the studies are likely to be underpowered to ascertain the risk of other solid cancers, particularly the risk of lymphoma following exposure to TNFi. In common with the data on NMSCs, most studies used the general population as a comparison cohort, and adjustment for confounding factors was inadequate.
A number of other aspects make interpretation of findings difficult. Confounding by indication (prognostic factors that may bias prescribing) is problematic for two of the eight studies identified; 20,21 excess alcohol and current smoking are factors that may influence clinician choice of which treatment to prescribe a patient. Also, the patients with psoriasis included in the identified studies were recruited from diverse geographical areas, which potentially influences baseline risk of cancer, the likelihood of seeking treatment, how events are reported, and how patients are treated. These factors, alone or in combination, further complicate interpretation of risk estimates: in relation to NMSCs for example, there is regional variation in use of psoralen plus UVA therapy and natural sun exposure as a treatment for psoriasis. Latency periods were not investigated in any of the included studies. Most cancers develop over a long period of time and so it is unlikely that biological therapy initiated close to a diagnosis of cancer is causally related. The eight studies identified include all cancers since initiation of treatment, with only three studies providing information on when the cancers developed. 20, 21, 27 None of the included studies summarized the length of time between a previous cancer and initiating biological therapy. Follow-up time, which may have an effect on the incidence of cancers reported, is highly variable among and within studies.
Patients often did not complete the planned duration of treatment or follow-up, and three studies only included cancers that developed during treatment and up to 30-70 days after treatment was discontinued. 24, 25, 27 In conclusion, studies show an increased risk of NMSCs, especially SCC, for patients with psoriasis receiving the TNFi therapies etanercept and adalimumab compared with the general U.S. population. The evidence to date suggests that there is no increased risk of cancers other than NMSC. However, there is no 'real-world' evidence and there are significant limitations to the studies identified, with the data largely from relatively short-term RCT and OLE studies, making it difficult to extrapolate to real-world practice. Therefore, there is a continuing need for pharmacovigilance.
Based on an estimated cancer frequency of 1 in 500 patients exposed only to conventional systemic therapies and a recruitment rate of 2 : 1 (biologic-exposed: biologic-naive), 18 250 and 9125 person-years of follow-up, respectively, would be needed to detect a two-fold increase in the risk of cancer; 31 if the cancer frequency is rarer (1 in 1000), the person-years of follow-up would increase to 36 550 for biologic-exposed and 18 275 for biologic-naive patients. The detail and scale of the data capture within ongoing pharmacovigilance registries, such as the British Association of Dermatologists Biologic Interventions Register, 31 as well as collaborative efforts through Psonet, 4 offers the opportunity to investigate cancer risk, specifically the risk attributable to biological therapy compared with patients exposed only to conventional systemic therapies and phototherapies. In order to determine whether there is a real increased risk of NMSCs with biological therapies, analyses need to take into account key confounders prevalent in the population (including excess alcohol and smoking) and the timing of events in relation to starting biological therapies, and report outcomes both as events and patients with events.
